This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hennig, R. Articles by Adrian, T. E. Search for Related Content PubMed PubMed Citation Articles by Hennig, R. Articles by Adrian, T. E.

5-Lipoxygenase, a Marker for Early Pancreatic Intraepithelial Neoplastic Lesions

Departments of ¹ Surgery, ² Pathology, and ³ Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois and ⁴ Department of Surgery, University of Heidelberg, Germany

Requests for reprints: Thomas E. Adrian, Department of Surgery, Northwestern University, Tarry Building, 4-711, 303 East Chicago Avenue, Chicago, IL 60611. Phone: 312-503-3489; Fax: 312-503-3491; E-mail: tadrian{at}northwestern.edu.

Pancreatic cancer has an abysmal prognosis because of late diagnosis. Therefore, it is important to identify risk factors if we are to be able to prevent and detect this cancer in an early, noninvasive stage. Pancreatic intraepithelial neoplasias (PanIN) are the precursor lesions which could be an ideal target for chemoprevention. This study shows up-regulation of 5-lipoxygenase (5-LOX) in all grades of human PanINs and early lesions of pancreatic cancer in two different animal models (EL-Kras mice and N-nitrosobis(2-oxopropyl)amine–treated hamsters) by immunohistochemistry. The results were consistent in all tissues examined, including seven chronic pancreatitis patients, four pancreatic cancer patients, one multiorgan donor, nine EL-Kras mice, and three N-nitrosobis(2-oxopropyl)amine–treated hamsters, all with PanINs. Overexpression of 5-LOX in NIH3T3 cells resulted in greater sensitivity of these cells to the growth inhibitory effects of the 5-LOX inhibitor Rev5901. These findings provide evidence that 5-LOX plays a key role in the development of pancreatic cancer. Furthermore, the lipoxygenase pathway may be a target for the prevention of this devastating disease.

This article has been cited by other articles:

				F. Cianchi, C. Cortesini, L. Magnelli, E. Fanti, L. Papucci, N. Schiavone, L. Messerini, A. Vannacci, S. Capaccioli, F. Perna, et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol. Cancer Ther., November 1, 2006; 5(11): 2716 - 2726. [Abstract] [Full Text] [PDF]

				M. Rakonjac, L. Fischer, P. Provost, O. Werz, D. Steinhilber, B. Samuelsson, and O. Radmark Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production PNAS, August 29, 2006; 103(35): 13150 - 13155. [Abstract] [Full Text] [PDF]